Do GLP-1, Amylin and Next-Generation Peptides Cause Muscle Loss? What the Research Actually Shows

As modern metabolic peptides produce increasingly large reductions in body weight, a new question is becoming just as important as weight loss itself:

What exactly is being lost?

Fat?

Muscle?

Water?

Other lean tissue?

This issue is becoming especially relevant with newer therapies capable of producing average body-weight reductions approaching or exceeding 20%.

That includes:

• GLP-1 receptor agonists
• GIP/GLP-1 dual agonists
• triple agonists such as retatrutide
• amylin combinations such as CagriSema
• emerging multi-receptor peptides

A major 2026 review concluded that reductions in lean body mass should not automatically be interpreted as skeletal-muscle loss, because measurements of lean mass also include body water, organs, connective tissue and other fat-free tissue. (PubMed⁠)

That distinction is crucial.

What Does “Lean Mass” Actually Mean?

Lean mass is everything in the body that is not classified as fat mass.

That includes:

• skeletal muscle
• organs
• water
• connective tissue
• bone-associated tissue
• other fat-free components

So if a body-composition scan reports a 5 kg reduction in lean mass, that does not necessarily mean 5 kg of muscle has disappeared.

This is one of the most common misunderstandings in discussions around GLP-1 therapies.

Why Does Lean Mass Fall During Weight Loss?

Almost every substantial form of weight loss reduces some lean tissue.

That occurs with:

• calorie restriction
• bariatric surgery
• lifestyle dieting
• pharmacological weight loss

When body mass falls significantly, the body simply does not need to support exactly the same amount of metabolically active tissue.

Some lean-mass reduction can therefore be a normal physiological consequence of becoming lighter.

The concern is when losses become disproportionately large or begin to affect:

• strength
• physical performance
• mobility
• metabolic health

Does GLP-1 Treatment Cause Muscle Loss?

The answer is more complicated than a simple yes or no.

GLP-1-based therapies clearly produce reductions in measured lean mass in many studies.

But the majority of lost body weight tends to come from fat mass rather than lean tissue.

A 2026 systematic review concluded that current studies suggest greater reductions in adiposity, but the available comparative evidence for true muscle preservation remains limited and highly variable. (PubMed⁠)

Researchers therefore cannot yet say precisely how much reported lean-mass loss represents actual contractile skeletal muscle.

Is Lean Mass the Same as Muscle Quality?

No.

A person can lose some muscle quantity while simultaneously improving muscle quality.

For example, obesity is commonly associated with fat accumulating within and around skeletal muscle.

This is sometimes called:

myosteatosis

or fatty infiltration of muscle.

Weight reduction can decrease this fat infiltration.

So even if total measured muscle volume falls slightly, the remaining tissue may become metabolically healthier.

Recent reviews have highlighted potential improvements involving:

• insulin sensitivity
• intramuscular fat
• inflammation
• mitochondrial function

during GLP-1-based therapy. (PubMed⁠)

Why Is This Becoming More Important Now?

Because the scale of pharmacological weight loss is increasing.

Older obesity drugs often produced relatively modest body-weight changes.

Modern treatments can produce much larger reductions.

A 2026 systematic review of 38 randomised trials found placebo-adjusted weight loss approaching:

• approximately 19% with tirzepatide
• more than 22% in retatrutide studies
• almost 24% in some emerging multiagonist programmes. (PubMed⁠)

The larger the total weight reduction, the more important body composition becomes.

What About Retatrutide?

Retatrutide is particularly relevant because of the magnitude of weight reduction seen in its Phase 3 programme.

In the 2026 TRIUMPH-1 trial involving 2,339 participants, average body-weight reduction reached:

• 17.6% at 4 mg
• 23.7% at 9 mg
• 25.0% at 12 mg

after 80 weeks, compared with 3.9% with placebo. (New England Journal of Medicine⁠)

When weight reductions reach this scale, understanding changes in:

• fat mass
• skeletal muscle
• bone
• physical function

becomes increasingly important.

Does Retatrutide Specifically Destroy Muscle?

There is currently no good evidence supporting such a simplistic claim.

The issue is much broader.

Rapid weight loss itself can create conditions that encourage lean-tissue loss, particularly when accompanied by:

• very low calorie intake
• inadequate protein
• little resistance exercise
• prolonged nausea
• reduced physical activity

The drug is only one part of that equation.

What About CagriSema?

CagriSema provides particularly interesting body-composition data because Novo Nordisk has reported DXA measurements from the REDEFINE programme.

In a body-composition subgroup of REDEFINE 1, approximately:

67% of the total weight lost was attributed to fat mass

and approximately:

33% to lean soft tissue.

Total fat mass fell by around 35.7%, while lean soft-tissue mass fell by around 14.4% over 68 weeks in the analysed subgroup. (Novo Nordisk⁠)

This means the treatment substantially improved the overall proportion of fat relative to lean tissue.

Is Losing 33% of Weight as Lean Tissue Bad?

Not automatically.

This is exactly why percentages need context.

Lean soft tissue includes much more than skeletal muscle.

And when someone becomes substantially lighter, reductions in:

• body water
• connective tissue
• supporting tissue
• organ-related mass

may contribute.

The clinically important question is whether the person also loses meaningful:

• muscle strength
• functional capacity
• mobility

Those outcomes have been much less consistently measured than DXA body composition. (PubMed⁠)

What Is Sarcopenia?

Sarcopenia is not simply having less lean mass.

It is a clinical condition involving loss of skeletal-muscle health, typically incorporating:

• reduced muscle strength
• reduced muscle quantity or quality
• impaired physical performance

That distinction matters enormously.

A person losing some lean tissue during successful obesity treatment does not automatically develop sarcopenia.

Recent reviews emphasize that current evidence is insufficient to conclude that GLP-1 therapy routinely causes sarcopenia. (PubMed⁠)

Who Could Be More Vulnerable?

Certain populations may deserve closer attention.

These include:

• older adults
• people already carrying little muscle
• physically inactive individuals
• people with very rapid weight loss
• people consuming too little protein
• people experiencing prolonged gastrointestinal adverse effects
• people with chronic disease affecting muscle

For someone starting with limited muscle reserves, even a relatively ordinary amount of lean-tissue loss could matter more.

Does Eating Less Automatically Mean Losing Muscle?

Not automatically.

But sustained energy restriction creates an environment where the body must obtain energy from stored tissues.

Ideally, most of that comes from fat.

But amino acids from muscle can also contribute.

The risk becomes greater when calorie intake falls sharply while:

• protein intake is inadequate
• resistance training is absent
• physical activity falls

This is one reason extreme appetite suppression may not always be desirable.

Why Does Protein Matter?

Skeletal muscle is constantly undergoing:

• protein synthesis
• protein breakdown

Adequate dietary protein provides amino acids needed for muscle-protein synthesis.

If someone eats dramatically less overall, they may also unintentionally consume much less protein.

A 2026 review of nutritional strategies during incretin treatment found that energy intake reductions of roughly 24–39% were reported across studies, while systematic assessment of protein and micronutrient intake remained surprisingly uncommon. (PubMed⁠)

That creates an important research gap.

Why Does Resistance Training Matter?

Muscle responds strongly to mechanical loading.

Resistance exercise tells the body:

this tissue is still needed.

During calorie restriction, this becomes particularly important.

Progressive resistance training can help support:

• muscle-protein synthesis
• strength
• functional capacity
• retention of lean tissue

A 2026 review specifically identified progressive resistance exercise and adequate protein intake among the most reasonable strategies for preserving skeletal muscle during GLP-1-based weight reduction. (PubMed⁠)

Does Cardio Protect Muscle?

Cardiovascular exercise provides many benefits.

But resistance training provides a more direct stimulus for preserving skeletal muscle.

The ideal programme during substantial weight reduction may therefore incorporate both:

• aerobic activity for cardiovascular fitness
• resistance training for muscle retention

rather than relying exclusively on one type of exercise.

What About Amylin Drugs?

Amylin therapies create an interesting new research question.

Compounds such as:

• cagrilintide
• petrelintide
• eloralintide
• lenbelintide
• ABBV-295

can substantially influence appetite.

Researchers now need to determine whether differences in:

• appetite suppression
• calorie intake
• nausea
• receptor signalling

translate into different patterns of body composition.

The answer is not yet clear.

Could Amylin Preserve More Muscle Than GLP-1?

This has been suggested as a possibility around some emerging compounds.

But it should not currently be treated as established fact.

The amylin field still lacks enough direct head-to-head body-composition data to conclude that amylin therapy universally preserves more skeletal muscle than GLP-1 therapy.

Future trials will need to measure:

• DXA body composition
• actual skeletal-muscle volume
• strength
• physical performance

rather than relying only on body weight.

Why Is Strength More Important Than a DXA Number?

Because muscle exists to perform work.

A body-composition scan can estimate how much lean tissue is present.

But it cannot fully tell us how well that tissue functions.

Researchers increasingly argue that future studies should include:

• grip strength
• leg strength
• walking performance
• physical-function testing

alongside body-composition measurements. (PubMed⁠)

That would provide a much more meaningful picture.

Could Metabolic Peptides Actually Improve Muscle Health?

Possibly.

This is the other side of the debate.

Obesity itself can negatively affect skeletal muscle through:

• insulin resistance
• inflammation
• reduced mobility
• fatty infiltration of muscle
• mitochondrial dysfunction

Weight reduction can improve several of these factors.

So a person may theoretically lose some absolute lean mass while gaining:

• better muscle insulin sensitivity
• less fat inside muscle
• improved mobility
• improved relative strength

That is why simply measuring kilograms of lean mass can be misleading.

What Is “Muscle Quality”?

Muscle quality refers roughly to how well muscle performs relative to its size.

A smaller but healthier muscle may function better than a larger muscle heavily infiltrated with fat.

Potential improvements in muscle quality could therefore offset some reduction in total tissue quantity.

This remains an important area of ongoing research.

What About Bone?

Very rapid weight reduction can also affect bone.

A 2026 review highlighted that changes in lean tissue during GLP-1 treatment may occur alongside changes in skeletal tissue and recommended that future studies pay closer attention to both muscle and bone health. (PubMed⁠)

This becomes particularly relevant during:

• prolonged treatment
• older age
• very large weight reduction

Could Future Drugs Specifically Protect Muscle?

Yes — and this may become one of the next major areas of metabolic drug development.

Researchers are already exploring combinations that pair powerful weight-loss treatments with compounds intended to influence:

• muscle growth
• muscle preservation
• body composition

However, these anabolic combination approaches remain experimental.

The goal would be different from simply producing greater weight reduction.

It would be:

lose more fat while preserving more functional lean tissue.

Could This Become the Next Competition Between Peptide Drugs?

Very possibly.

The first generation of metabolic drugs was judged largely on:

How much weight does it produce?

The next generation may increasingly be judged on:

What kind of weight does it produce?

Two drugs could theoretically produce the same 20% reduction in body weight but differ substantially in:

• fat loss
• muscle retention
• strength
• metabolic health

That would be clinically meaningful.

Why Could Reta+ Make This Even More Important?

Experimental combinations such as cagrilintide + retatrutide may produce even stronger effects on energy balance.

If increasingly powerful combinations reduce appetite further, researchers will need to ensure that the resulting weight reduction does not compromise:

• nutrient intake
• lean tissue
• physical function

The larger the pharmacological effect becomes, the more important nutritional and body-composition monitoring becomes.

Is “Muscle Wasting” the Right Phrase?

Usually not.

Terms such as “muscle wasting” can imply pathological destruction of skeletal muscle.

Current evidence does not support describing ordinary lean-mass changes during incretin treatment this way across the board.

A more accurate phrase is:

lean-mass reduction during weight loss

until direct measures demonstrate clinically meaningful muscle loss.

What Should Future Trials Measure?

Future metabolic-drug trials should ideally evaluate:

• total fat mass
• visceral fat
• lean soft tissue
• skeletal-muscle volume
• muscle strength
• physical performance
• protein intake
• exercise behaviour
• bone density

This would provide a far more complete picture than body weight alone.

The Bigger Shift: Weight Loss vs Body Composition

Metabolic pharmacology is entering a new stage.

When drugs produced relatively modest weight reduction, the headline percentage was often enough to differentiate them.

That is changing.

Retatrutide, tirzepatide, CagriSema and newer multiagonists are capable of producing much larger reductions. (New England Journal of Medicine⁠)

As those numbers climb, the quality of weight loss becomes increasingly important.

The Bottom Line

Modern GLP-1, amylin and multi-receptor therapies can reduce both fat mass and measured lean mass.

But lean mass is not synonymous with skeletal muscle.

It includes:

• muscle
• water
• organs
• connective tissue
• other fat-free tissue

Current research suggests that most pharmacological weight loss comes from fat, while the clinical significance of accompanying lean-tissue reduction remains incompletely understood. (PubMed⁠)

CagriSema body-composition data provide a useful example: approximately 67% of total weight loss came from fat mass and 33% from lean soft tissue in a REDEFINE 1 DXA subgroup. (Novo Nordisk⁠)

The major concern is therefore not simply whether lean mass decreases.

It is whether people retain:

functional skeletal muscle, adequate nutrition, strength and physical performance.

Current evidence supports paying particular attention to:

• adequate protein intake
• progressive resistance exercise
• avoiding excessive nutritional restriction
• monitoring people at greater risk of muscle loss. (PubMed⁠)

As metabolic therapies become increasingly powerful, success may ultimately be judged not only by how much weight they remove, but by how much fat they remove while preserving healthy, functional tissue.

This article is for research and educational purposes only. Body-composition changes vary between individuals, and emerging peptide therapies may remain investigational.